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Osteoprotegerin, sRANKL and sRANKL/ 
/OPG ratio in pseudosynovial fluid from 
patients with aseptic loosening of total 
hip prosthesis
ABSTRACT
Background. Total hip replacement is the final solution in advanced osteoarthritis. The survival time of 
the implant significantly depends on the condition of the bone in which it has been located. Upsetting 
the balance in the RANK/RANKL/OPG system can lead to the development of bone metabolic disorders 
leading to bone loss. The aim of this study was to evaluate the osteoprotegerin (OPG) and soluble RANKL 
(sRANKL) concentrations in the pseudosynovial fluid in women with aseptic loosening of total hip prosthesis.
Methods. OPG and sRANKL concentrations were assayed in the pseudosynovial fluid collected from 
20 women during the revision total hip arthroplasty (THA) (group R), and in the synovial fluid of 13 women 
in the end-stage of idiopathic osteoarthritis collected during primary THA (group P). OPG and sRANKL 
were measured using commercially available ELISA kits.
Results. OPG concentration was significantly lower, and sRANKL concentration was significantly higher, 
in group R than in group P. The sRANKL/OPG ratio in group R was significantly higher than in group P. 
The average total joint endoprosthesis survival time was 8.6 (SD 3.9) years. The OPG concentration was 
slightly lower in patients with a time interval shorter than 8.6 years. The sRANKL/OPG ratio was higher in 
women with a shorter implant survival time. 
Conclusion. Higher sRANKL/OPG ratio in the pseudosynovial fluid contributes to increased resorption of 
bone tissue surrounding total hip endoprosthesis, leading to its aseptic loosening.
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Introduction
Osteoarthritis, a result of both biological and 
mechanical factors leading to a disturbance of the 
balance within a joint between degradation and repair 
processes, affects equally chondrocytes of the articu-
lar cartilage, cartilage matrix and subchondral bone. 
The disease is characterised by certain morphological 
changes in the joints, and also by visible biochemical 
and biomechanical changes [1–4]. The degeneration 
process within the joint leads to a significant limitation 
of motor abilities and disability. Total hip endoprosthesis 
implantation is usually the final solution [4, 5].
The survival times of implanted hip endoprosthesis 
may differ [5–7]. It has been estimated that, on average, 
a total hip endoprosthesis lasts in a good condition for 
ten years [6, 7]. The survival time of the joint implant 
significantly depends on the condition of the bone in 
which it has been located [4, 6]. Osteolysis, which 
occurs around the implant, has been demonstrated to 
be one of the numerous causes of joint endoprosthesis 
loosening [8].
Osteoprotegerin (OPG) is considered to be a factor 
which protects against osteoclastogenesis both in vitro 
and in vivo [9–12]. Osteoprotegerin blocks the inter-
action of the RANK receptor localised on the surface 
of osteoclasts with its specific ligand (RANKL), which 
inhibits signalling for preosteoclasts to undergo matu-
ration. This interaction directly influences the process of 
bone remodelling [13–15]. Disturbing the balance in the 
RANK/RANKL/OPG system can lead to the development 
of numerous bone metabolic disorders with accompa-
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nying bone loss [13, 15–18]. Recent results suggest 
that modulation of the OPG/RANKL system may be 
an interesting target for future osteoarthritis treatment. 
OPG is not only a decoy receptor for RANKL, but also 
acts as a modulator of RANKL half-life [13]. 
The composition of joint fluid reflects the local en-
vironment. Similarly, tests performed in the pseudosy-
novial fluid give a specific image of processes that take 
place in the immediate surroundings of the implanted 
joint endoprosthesis [19, 20]. An increased production 
of joint fluid may be associated with a failure of total 
hip or knee arthroplasty. It has been supposed that the 
fluids from failed arthroplasties had shown higher cyto-
toxicity and higher levels of wear particles, host cells, 
and proteins, with more severe bone loss. However, the 
latest data has not confirmed a toxic influence of syno-
vial fluids from failed total hip or knee joint prostheses 
on in vitro cultured osteoblasts [21].
We aimed to evaluate the osteoprotegerin and 
RANKL concentrations in the pseudosynovial fluid in 
women with osteoarthritis, after aseptic loosening of 
total hip prosthesis.
Patients and methods
Osteoprotegerin and sRANKL concentrations were 
assayed in joint fluid collected from 33 women who 
underwent hip surgery. 20 women (aged 62 ± 12 years) 
had revision surgery because of aseptic loosening of 
endoprosthesis (we called this group R —Revision 
group). The second group (group P — Primary group) 
consisted of 13 women (aged 67 ± 7 years) in the end-
stage of osteoarthritis in whom first total hip arthroplasty 
(THR) had been performed. All revision cases had orig-
inally been operated on for primary osteoarthritis. The 
interval between primary and revision surgery was 
8.6 ± 3.9 years. 
Informed consent was given by all participants, 
and the procedures were approved by the local Bio-
ethics Committee.
Samples of synovial and pseudosynovial fluid were 
collected with a sterile syringe before incising the 
capsule. After collection, samples of synovial fluid and 
pseudosynovial fluid were centrifuged, treated with hyal-
uronidase (3,000 IU/mL, type IV S, Sigma Chemical Co., 
USA) in 0.15 M phosphate buffer, pH 5.29 for 10 min at 
37°C as previously described by us (Sypniewska et al. 
2002) to reduce viscosity and stored at –70°C for up to 
one month before the analyses. 
All specimens were assayed for osteoprotegerin 
(OPG) and soluble RANKL (sRANKL) using commer-
cially available ELISA kits (Immun Diagnostik, Bio-
medica Gruppe, Germany). These tests use specific 
animal biotinylated polyclonal anti-OPG or anti-sRANKL 
antibodies and streptavidin-HRP as conjugate. The 
detection limit for OPG was 0.14 pmol/l. The detection 
limit for sRANKL was 0.08 pmol/L. The intra assay CVs 
were < 10%.
Statistics
Statistical analysis was done with the use of 
Mann-Whitney’s U test. Spearman correlation coef-
ficient R was used. A p value ≤ 0.05 was considered 
statistically significant. 
Results
The osteoprotegerin concentration in the pseudo-
synovial fluid taken from women during the revision 
surgery (group R) was significantly lower than that 
in the joint fluid of women in which primary total hip 
arthroplasty had been performed (group P). On the 
other hand, the concentration of sRANKL was signifi-
cantly higher in group R. The sRANKL/OPG ratio in the 
joint fluid of group P was significantly lower than in the 
pseudosynovial fluid of women from group R (Tab. 1). 
No significant correlation between the OPG and 
sRANKL concentration in the joint fluid was found in 
either group (OPG/sRANKL R = –0.11; R = 0.32 in 
groups R and P, respectively).
In both groups, there was no significant correlation 
of the OPG concentration in the pseudosynovial or sy-
novial fluid with age (OPG/age: R = –0.05; R = –0.51 in 
groups R and P, respectively). A significant correlation of 
sRANKL in pseudosynovial fluid with age was observed 
in the revision surgery group (sRANKL/age: R = 0.49; 
Table 1. OPG, sRANKL concentrations and sRANKL/OPG ratio in pseudosynovial or synovial fluid from patients with 
revision total hip arthroplasty (group R) and patients with primary total hip arthroplasty (group P)
Group R 
[mean ± SD]
Group P 
[mean ± SD] p ≤ 
OPG [pg/mL] 311 ± 109 587 ± 80 0.000005
sRANKL [pg/mL] 58.5 ± 69.9 19.4  ± 7.8 0.05
sRANKL/OPG ratio 0.20 ± 0.24 0.09 ± 0.17 0.02
OPG — osteoprotegerin; sRANKL — soluble RANKL
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p ≤ 0.03). In patients with primary hip arthroplasty, there 
was no correlation between synovial fluid concentration 
of sRANKL and age (sRANKL/age: R = –0.36). 
The average total hip endoprosthesis survival time 
was 8.6 ± 3.9 years. In 50% of women from group R, 
the period between the first and the revision surgery 
was 4-7 years (ST group — Short Time). In the other 
half of the women, the implant survival time was longer: 
9–16 years (LT group — Long Time).
Women with an implant survival time of shorter 
than 8.6 years were not significantly older than patients 
with longer prosthesis survival time (64 ± 15 years 
vs. 59 ± 9 years, respectively).
OPG concentration in the pseudosynovial fluid in 
women with revision surgery performed earlier than 
8.6 years after primary THA (the ST group) was slightly 
lower than the OPG concentration in the fluid taken from 
women whose time of implant survival was longer (LT 
group). The sRANKL concentration in the pseudosyno-
vial fluid in women with a shorter time of implant survival 
was also insignificantly lower than the sRANKL concen-
tration in the fluid from women with a longer period of 
implant survival. The sRANKL/OPG ratio was higher in 
women with a shorter time of implant survival (Tab. 2). 
There was no significant correlation between the 
OPG or sRANKL concentration and period of prima-
ry operation to revision surgery (OPG/time interval: 
R = 0.48; sRANKL/time interval: R=0.26). The im-
plant survival time was inversely correlated with the 
sRANKL/OPG ratio (R = –0.42; p ≤ 0.05).
Discussion
The survival times of joint endoprostheses differ, 
and it has been estimated that on average 30% of total 
hip endoprostheses undergo aseptic loosening within 
10–14 years [7]. The reason for hip endoprosthesis 
loosening has not been defined yet. Osteolysis, which 
occurs around the implant, has been mentioned among 
numerous possible causes [6–8, 22, 23].
Osteoprotegerin is considered to be a cytokine 
protecting the bone from excessive resorption [24, 25]. 
A proper balance in the RANKL/OPG system is essential 
for the osteoclast’s activity, and its uncoupling leads to 
significant disturbances in bone turnover [13, 24, 26, 27]. 
As has been suggested by Malik et al., genetically 
determined disturbances in the RANK/RANKL/OPG 
system may have the essential influence on joint endo-
prosthesis survival [28]. Interface tissue fibroblasts are 
able to produce RANK ligand. RANKL, which is present 
in pseudosynovial fluid, can induce osteoclastogenesis 
during the loosening process [29, 30].
Others have observed that the OPG concentration in 
the synovial fluid of those who suffer from osteoarthritis in-
creases with the progress of degeneration changes [31]. 
In patients with a total hip endoprosthesis, the bone 
is in direct contact with the pseudosynovial fluid filling 
the joint space [21]. According to Gehrke et al. [32], 
macrophages and osteoclasts present in the immediate 
surroundings of the prosthesis play the essential role in 
the activation of bone remodelling and its destruction. 
However, osteoprotegerin could be a locally efficient 
preventative factor [32]. Failure of implantation leads 
to an increase of its wear products, something that 
will initiate inflammation in the interface membrane. 
Inflammatory changes cause a whole cascade of bio-
logical phenomena that enhance bone resorption in the 
surroundings of a prosthesis [6, 20, 22]. As has been 
shown in joint disorders with intensified inflammation, 
decreased expression of osteoprotegerin in joint tissues 
was observed [33]. We found that OPG concentration in 
the pseudosynovial fluid from patients with a loosened 
endoprosthesis was almost two fold lower than in the 
synovial fluid taken during primary THA. This probably 
results from inflammation developing in the immediate 
surroundings of the implanted endoprosthesis [20]. 
Lower OPG concentration in the pseudosynovial fluid 
from patients with aseptically failed total joint prostheses 
has also been observed by Gallo et al. [21]. However, 
Wang et al. did not find significant differences in the 
OPG levels in the synovial fluid between patients with 
loosened total hip arthroplasty (THA) and primary THA 
patients [34]. 
A higher concentration of sRANKL in patients with 
revision accompanies the decreased osteoprotegerin 
concentration in the pseudosynovial fluid. According to 
Goater et al., the inflammation may be caused by wear 
debris which may stimulate the expression of RANKL 
receptor, something that intensifies osteolysis causing 
the implant to loosen [35]. Increased RANKL levels in 
the pseudosynovial fluid were found in our study in pa-
Table 2. OPG, sRANKL and sRANKL/OPG ratio in pseudosynovial fluid from patients with revision total hip arthroplasty  
with implant survival time shorter than 8.6 years (ST group) and with implant survival time longer than 8.6 years (LT group)
ST group [mean±SD] LT group [mean±SD] p ≤
OPG [pg/mL] 275 ± 103 347 ± 106 NS
sRANKL [pg/mL] 81 ± 94 35.8± 19.7 NS
sRANKL/OPG ratio 0.28 ± 0.31 0.12± 0.10 NS
NS — not significant; OPG — osteoprotegerin; sRANKL — soluble RANKL
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tients who underwent the revision surgery. Similar data 
were recently reported by Wang et al. [34] in patients 
with loosened THA and by Gallo et al. [21] in patients 
with aseptic prosthesis loosening. 
The excessive loss of bone mass is connected to an 
increase of the sRANKL/OPG coefficient [24, 26, 27]. 
Essentially, a higher sRANKL/OPG ratio in women with 
aseptic loosening of total hip endoprosthesis suggests 
a disturbed balance in the RANK/RANKL/OPG system, 
which may cause excessive resorption of the bone 
surrounding the endoprosthesis. Similarly to our re-
sults, a higher sRANKL/OPG ratio has been reported 
by others [21, 34].
Implanted endoprostheses have only a limited so 
called ‘survival time’ [6, 7]. In the discussed work, the 
average time between the primary and revision surgery 
was 8.6 years (4–16 years). According to Granchi et 
al., high serum OPG concentration means a good 
prognosis concerning the survival of the implanted en-
doprosthesis, whereas increased RANKL concentration 
correlates with an increased level of bone resorption in 
the surroundings of the prosthesis [36]. Testing the fluid 
taken from the immediate surroundings of the implanted 
endoprosthesis allows more accurate evaluation of local 
processes in the joint [20]. The balance between RANKL 
and OPG concentrations seems to be more important 
than individual OPG or RANKL value. We observed that 
the shorter the interval that elapses between the primary 
and revision THA, the higher the sRANKL/OPG ratio. 
The same was suggested earlier by Granchi et al. [36]. 
Osteolysis is associated with aseptic loosening 
of total hip endoprosthesis [6, 20, 22]. The results of 
Wang et al. suggest that ultra-high molecular weight 
polyethylene particles (UHMWPE) may induce the 
over-expression of RANKL, inflammatory cytokines and 
chemokines in the periprosthetic microenvironment 
[34]. These molecules by independent or synergistic 
actions result in periprosthetic osteolysis and loosening 
of THA. Low concentration of bone protecting factor os-
teoprotegerin, with simultaneously high RANKL, seems 
to be an important reason for premature loosening of 
total hip endoprosthesis and shortening of its survival 
[37, 38]. High RANKL levels and low OPG concentra-
tions are also in agreement with the theory of aseptic 
loosening and periprosthetic osteolysis [21]. 
From the practical point of view, it would be of 
interest as to whether serum OPG and RANKL could 
be a measure of risk of bone osteolysis after endopros-
thesis implantation. 
Conclusions
A higher sRANKL vs OPG ratio in the pseudosynovial 
fluid contributes to increased bone resorption in the 
periprosthetic microenvironment, leading to aseptic 
prosthesis loosening.
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